

**-Remarks-**

Claims 1-17 were pending. Examiner rejected claim 1 and objected to claims 2-6 and 8-11. By this amendment, claims 1-6 and 9-17 remain pending. Claims 7-8 are canceled without prejudice or disclaimer. Claims 2 and 11 are amended to place the claims into better form. They are not narrowing amendments nor are they made in response to a rejection by Examiner. No new matter is added. Reconsideration and withdrawal of the rejection and objection is respectfully requested.

**Response to Novelty Rejection.**

Claim 1 was rejected under 35 USC § 102 as being anticipated by Tuntulani et al., Bulletin of the Korean Chemical Society, 21(12), 1245-1248, 2000, based on an Abstract by CAPLUS. Specifically, Examiner asserts that the compound shown in the Abstract anticipates the compound generically claimed in claim 1.

Applicants respectfully traverse.

However, in order to advance the prosecution, Applicants amended claim 1 to exclude the compound taught by Tuntulani et al., from the scope of formula I.

Accordingly, Applicants respectfully request that Examiner reconsider and withdraw the rejection of claim 1 under 35 USC § 102.

**Response to Claim Objection.**

Examiner stated that claims 2-6 and 8-11 were objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form. By this present Amendment, claim 11 was rewritten in independent form. Nevertheless, with entry of the present amendments, Applicants respectfully assert that claim 1 is allowable. Therefore, claims 2-6 and 8-11 would not be considered dependent from a rejected base claim.

Accordingly, Applicants respectfully request that Examiner reconsider and withdraw the objection to claims 2-6 and 8-11.

**Response to Election/Restriction Concerns.**

Examiner noted that Applicants must cancel non-elected claims in order to completely reply to a final rejection. Since the present rejection is not a final rejection, Applicants have elected not to cancel claims 12-17 at this time. Claim 7 was cancelled by this present Amendment.

**-Conclusion-**

Applicants, having responded to all points and concerns raised by Examiner, believe this application to be in condition for allowance. An early and favorable action is respectfully requested.

Respectfully submitted,

Dated: June 25/07

A handwritten signature in dark ink, appearing to read 'W. Mulholland, II', is written over a horizontal line.

William F. Mulholland, II  
Attorney for Applicants  
Reg. No. 45,684

Pfizer Inc.  
Patent Department  
Eastern Point Road  
Groton, CT 06340  
(860) 715-5590